Dr. Alejandro Alva, M.D.
Psychiatry (Psychiatry Physician)
- Medicare participating
At a glance
- Years since graduation
- 36
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 122
Licensed in California since 1997, according to the Medical Board of California. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Psychiatry Physician primary
CA license A062396 (first issued 1997; current)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Medical groups
- Pacific Neuropsychiatric Specialists Inc (72 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 122
- Services billed
- 508
- Patients’ average age
- 63
| Service | Times | Patients |
|---|---|---|
| Psychotherapy with evaluation and management visit, 30 minutes | 233 | 92 |
| Established patient office or other outpatient visit, 30-39 minutes | 135 | 75 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 100 | 15 |
| Established patient office or other outpatient visit, 40-54 minutes | 96 | 43 |
| Established patient office or other outpatient visit, 20-29 minutes | 24 | 15 |
| New patient office or other outpatient visit, 60-74 minutes | 20 | 20 |
| Administration of psychological or neuropsychological test by technician, first 30 minutes | 14 | 13 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 23 companies reported 268 payments worth $77,471 in total to this clinician.
| Iti, Inc. (d/b/a Intra-cellular Therapies, Inc.) | $37,716 |
|---|---|
| Teva Pharmaceuticals USA, Inc. | $18,247 |
| Alkermes, Inc. | $8,733 |
| Neurocrine Biosciences, Inc. | $8,523 |
| Axsome Therapeutics, Inc. | $1,001 |
| AbbVie Inc. | $689 |
| Janssen Pharmaceuticals, Inc | $421 |
| Luye Pharma (USA) LTD. | $386 |
| Compensation for services other than consulting (speaking, faculty) | $46,678 |
|---|---|
| Consulting Fee | $16,750 |
| Food and Beverage | $7,982 |
| Travel and Lodging | $6,056 |
| Education | $5.45 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. Apr 3, 2025 | Compensation for services other than consulting (speaking, faculty) AUSTEDO XR · Central Nervous System | $8,893 |
| Neurocrine Biosciences, Inc. Mar 25, 2025 | Consulting Fee INGREZZA · Neuropsychiatry | $7,188 |
| Iti, Inc. (d/b/a Intra-cellular Therapies, Inc.) Oct 23, 2025 | Compensation for services other than consulting (speaking, faculty) CAPLYTA · PSYCHIATRY | $4,440 |
| Iti, Inc. (d/b/a Intra-cellular Therapies, Inc.) Nov 17, 2025 | Consulting Fee CAPLYTA · PSYCHIATRY | $4,440 |
| Iti, Inc. (d/b/a Intra-cellular Therapies, Inc.) Dec 12, 2025 | Compensation for services other than consulting (speaking, faculty) CAPLYTA · PSYCHIATRY | $4,440 |
| Iti, Inc. (d/b/a Intra-cellular Therapies, Inc.) Dec 12, 2025 | Compensation for services other than consulting (speaking, faculty) CAPLYTA · PSYCHIATRY | $3,885 |
| Iti, Inc. (d/b/a Intra-cellular Therapies, Inc.) Dec 17, 2025 | Compensation for services other than consulting (speaking, faculty) CAPLYTA · PSYCHIATRY | $3,885 |
| Teva Pharmaceuticals USA, Inc. Apr 10, 2025 | Compensation for services other than consulting (speaking, faculty) AUSTEDO XR · Central Nervous System | $3,250 |
| Teva Pharmaceuticals USA, Inc. Mar 27, 2025 | Compensation for services other than consulting (speaking, faculty) AUSTEDO XR · Central Nervous System | $3,250 |
| Alkermes, Inc. Sep 26, 2025 | Compensation for services other than consulting (speaking, faculty) LYBALVI; LYBALVI; LYBALVI · CNS | $3,060 |
All 34 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Iti, Inc. (d/b/a Intra-cellular Therapies, Inc.) Dec 17, 2025 | Compensation for services other than consulting (speaking, faculty) CAPLYTA · PSYCHIATRY | $3,885 |
| Iti, Inc. (d/b/a Intra-cellular Therapies, Inc.) Dec 17, 2025 | Compensation for services other than consulting (speaking, faculty) CAPLYTA · PSYCHIATRY | $2,220 |
| Iti, Inc. (d/b/a Intra-cellular Therapies, Inc.) Dec 12, 2025 | Compensation for services other than consulting (speaking, faculty) CAPLYTA · PSYCHIATRY | $4,440 |
| Iti, Inc. (d/b/a Intra-cellular Therapies, Inc.) Dec 12, 2025 | Compensation for services other than consulting (speaking, faculty) CAPLYTA · PSYCHIATRY | $3,885 |
| Iti, Inc. (d/b/a Intra-cellular Therapies, Inc.) Dec 12, 2025 | Compensation for services other than consulting (speaking, faculty) CAPLYTA · PSYCHIATRY | $2,775 |
| Iti, Inc. (d/b/a Intra-cellular Therapies, Inc.) Dec 12, 2025 | Compensation for services other than consulting (speaking, faculty) CAPLYTA · PSYCHIATRY | $2,220 |
| Iti, Inc. (d/b/a Intra-cellular Therapies, Inc.) Dec 9, 2025 | Travel and Lodging CAPLYTA · PSYCHIATRY · travel to HEMET, CA · in-kind | $894 |
| Iti, Inc. (d/b/a Intra-cellular Therapies, Inc.) Dec 4, 2025 | Travel and Lodging CAPLYTA · PSYCHIATRY · travel to MENIFEE, CA · in-kind | $833 |
| Iti, Inc. (d/b/a Intra-cellular Therapies, Inc.) Nov 17, 2025 | Consulting Fee CAPLYTA · PSYCHIATRY | $4,440 |
| Iti, Inc. (d/b/a Intra-cellular Therapies, Inc.) Nov 11, 2025 | Travel and Lodging CAPLYTA · PSYCHIATRY · travel to ONTARIO, CA · in-kind | $992 |
| Iti, Inc. (d/b/a Intra-cellular Therapies, Inc.) Oct 23, 2025 | Compensation for services other than consulting (speaking, faculty) CAPLYTA · PSYCHIATRY | $4,440 |
| Alkermes, Inc. Oct 16, 2025 | Compensation for services other than consulting (speaking, faculty) LYBALVI; LYBALVI; LYBALVI · CNS | $3,060 |
| Iti, Inc. (d/b/a Intra-cellular Therapies, Inc.) Oct 14, 2025 | Travel and Lodging CAPLYTA · PSYCHIATRY · travel to PASADENA, CA · in-kind | $852 |
| Iti, Inc. (d/b/a Intra-cellular Therapies, Inc.) Oct 4, 2025 | Travel and Lodging CAPLYTA · PSYCHIATRY · travel to CHARLOTTE, NC · in-kind | $1,764 |
| Iti, Inc. (d/b/a Intra-cellular Therapies, Inc.) Oct 4, 2025 | Travel and Lodging CAPLYTA · PSYCHIATRY · travel to CHARLOTTE, NC · in-kind | $275 |
| Iti, Inc. (d/b/a Intra-cellular Therapies, Inc.) Oct 4, 2025 | Travel and Lodging CAPLYTA · PSYCHIATRY · travel to CHARLOTTE, NC · in-kind | $91.67 |
| Iti, Inc. (d/b/a Intra-cellular Therapies, Inc.) Oct 4, 2025 | Travel and Lodging CAPLYTA · PSYCHIATRY · travel to CHARLOTTE, NC · in-kind | $44.30 |
| Teva Pharmaceuticals USA, Inc. Oct 1, 2025 | Compensation for services other than consulting (speaking, faculty) AUSTEDO XR · Central Nervous System | $1,300 |
| Alkermes, Inc. Sep 26, 2025 | Compensation for services other than consulting (speaking, faculty) LYBALVI; LYBALVI; LYBALVI · CNS | $3,060 |
| Neurocrine Biosciences, Inc. Sep 20, 2025 | Travel and Lodging INGREZZA · Neuropsychiatry · travel to San Diego, CA · in-kind | $9.24 |
| Teva Pharmaceuticals USA, Inc. Aug 25, 2025 | Consulting Fee AUSTEDO XR · Central Nervous System | $705 |
| Alkermes, Inc. Aug 13, 2025 | Consulting Fee LYBALVI; LYBALVI; LYBALVI · CNS | $960 |
| Iti, Inc. (d/b/a Intra-cellular Therapies, Inc.) Jun 4, 2025 | Consulting Fee CAPLYTA · PSYCHIATRY | $2,498 |
| Alkermes, Inc. May 2, 2025 | Consulting Fee LYBALVI; LYBALVI; LYBALVI · CNS | $960 |
| Teva Pharmaceuticals USA, Inc. Apr 10, 2025 | Compensation for services other than consulting (speaking, faculty) AUSTEDO XR · Central Nervous System | $3,250 |
| Teva Pharmaceuticals USA, Inc. Apr 10, 2025 | Travel and Lodging AUSTEDO XR · Central Nervous System · travel to Newport Beach, CA | $25.20 |
| Teva Pharmaceuticals USA, Inc. Apr 10, 2025 | Travel and Lodging AUSTEDO XR · Central Nervous System · travel to Newport Beach, CA | $5.00 |
| Teva Pharmaceuticals USA, Inc. Apr 3, 2025 | Compensation for services other than consulting (speaking, faculty) AUSTEDO XR · Central Nervous System | $8,893 |
| Teva Pharmaceuticals USA, Inc. Mar 27, 2025 | Compensation for services other than consulting (speaking, faculty) AUSTEDO XR · Central Nervous System | $3,250 |
| Teva Pharmaceuticals USA, Inc. Mar 27, 2025 | Travel and Lodging AUSTEDO XR · Central Nervous System · travel to Corona Del Mar, CA | $22.40 |
| Teva Pharmaceuticals USA, Inc. Mar 27, 2025 | Travel and Lodging AUSTEDO XR · Central Nervous System · travel to Corona Del Mar, CA | $5.00 |
| Neurocrine Biosciences, Inc. Mar 25, 2025 | Consulting Fee INGREZZA · Neuropsychiatry | $7,188 |
| Neurocrine Biosciences, Inc. Mar 1, 2025 | Travel and Lodging INGREZZA · Neuropsychiatry · travel to San Diego, CA · in-kind | $243 |
| Janssen Pharmaceuticals, Inc Feb 4, 2025 | Education in-kind | $5.45 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 2 industry-funded studies in 2025, from 1 companies. The companies reported $34,391 in research payments for these studies, mostly to the institutions running them.
- A Study of Aticaprant in Adult and Elderly Participants With Major Depressive Disorder (MDD) (VENTURA-LT)
Janssen Research & Development, LLC - A Randomized, Double-blind, Multicenter, Placebo-controlled Study to Evaluate the Efficacy, Safety and Tolerability of Aticaprant 10 mg and 5 mg as Adjunctive Therapy in Adult Participants with Major Depressive Disord…
Janssen Research & Development, LLC
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.